<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460381</url>
  </required_header>
  <id_info>
    <org_study_id>14397</org_study_id>
    <secondary_id>H9P-EW-LNDZ</secondary_id>
    <nct_id>NCT01460381</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Genotype on LY2216684</brief_title>
  <official_title>A Study to Investigate the Effect of CYP2C19 Phenotype on the Pharmacokinetics of LY2216684 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine
      on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be
      documented.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve from time 0 to infinity [AUC(0-∞)] of LY2216684 in cytochrome P450 (CYP)2C19 extensive metabolizers (EM) versus poor metabolizers (PM)</measure>
    <time_frame>Predose up to 120 hours post administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum observed plasma concentration (Cmax) of LY2216684 in cytochrome P450 (CYP)2C19 extensive metabolizers (EM) versus poor metabolizers (PM)</measure>
    <time_frame>Predose up to 120 hours post administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time to maximum observed plasma concentration (tmax) in cytochrome P450 (CYP)2C19 extensive metabolizers (EM) versus poor metabolizers (PM)</measure>
    <time_frame>Predose up to 120 hours post administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve from time 0 to infinity [(AUC(0-∞)] of LY2216684 + Quinidine in cytochrome P450 (CYP)2C19 poor metabolizers (PM)</measure>
    <time_frame>Predose up to 120 hours post administration of Quinidine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum observed plasma concentration (Cmax) of LY2216684 + Quinidine in CYP2C19 poor metabolizers</measure>
    <time_frame>Predose up to 120 hours post administration of Quinidine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to maximum observed plasma concentration (tmax)in CYP2C19 poor metabolizers</measure>
    <time_frame>Predose up to 120 hours post administration of Quinidine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>LY2216684 + Quinidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 (Day -1 up to Day 6), a single 18 mg oral dose of LY2216684 will be administered on Day 1 for CYP2C19 poor metabolizers (PM). In Period 2 (Day 7 up to Day 16), a 300 mg oral dose of quinidine sulfate controlled release (CR) will be administered once daily (QD) on Days 8 through 15 and a single 18 mg oral dose of LY2216684 will be administered on Day 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2216684</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1, a single 18 mg oral dose of LY2216684 will be administered on Day 1 for CYP2C19 extensive metabolizers (EM) participants. EM participants do not participate in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2216684 + Quinidine</arm_group_label>
    <arm_group_label>LY2216684</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2216684 + Quinidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Male participants: Agree to use a reliable method of birth control during the study
             and for 1 month following the last dose of study drug

          -  Female participants: Are women of child-bearing potential who test negative for
             pregnancy at the time of enrollment, have used a reliable method of birth control (not
             including hormonal contraceptives) for 4 weeks prior to administration of study drug,
             and agree to use a reliable method of birth control during the study and for 1 month
             following the last dose of the study drug or; Are women not of child-bearing potential
             due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal
             ligation/occlusion) or menopause (at least 1 year without menses or 6 months without
             menses and a follicle stimulating hormone [FSH] level &gt;40 mIU/mL)

          -  Have a body weight &gt;50 kg

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator

          -  Have venous access sufficient to allow for blood sampling as per the protocol

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent approved by Lilly and the institutional review
             board (IRB) governing the site

          -  Have normal blood pressure (BP) and pulse rate (PR) (sitting position) as determined
             by the investigator

          -  Are predicted to have cytochrome P450 (CYP)2C19 extensive metabolizer (EM) or poor
             metabolizer (PM) phenotypes as determined by genotyping assessment

          -  Are predicted to have CYP2D6 EM phenotype as determined by genotyping assessment.

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued within the last 30 days
             from, a clinical trial involving an investigational product; or are concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Have known allergies/intolerance to LY2216684 or quinidine, related compounds, or any
             components of the formulation

          -  Are persons who have previously received the investigational product in this study,
             have completed or withdrawn from this study or any other study investigating LY2216684
             within 6 months prior to Screening.

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study

          -  Have a history or show evidence of significant active neuropsychiatric disease or have
             a history of suicide attempt or ideation

          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Are women with a positive pregnancy test or women who are lactating

          -  Intend to use over-the-counter or prescription medication within 14 days prior to
             dosing or during the study unless deemed acceptable by the investigator and Sponsor's
             medical monitor. Exceptions include influenza vaccinations, the use of topical
             medication (provided there is no evidence of chronic dosing with the risk of systemic
             exposure), occasional use of acetaminophen/paracetamol/ibuprofen, and hormone
             replacement therapy including thyroid replacement (stable dose for at least 1 month).

          -  Have donated blood of more than 500 mL within the last month

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females), or are unwilling to stop alcohol consumption 48 hours prior
             to dosing in Period 1 until Discharge (1 unit = 12 oz or 360 mL of beer; 5 oz or 150
             mL of wine; 1.5 oz or 45 mL of distilled spirits)

          -  In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study

          -  Consume 5 or more cups of coffee (or other beverages of comparable caffeine content)
             per day, on a habitual basis, or any participants unwilling to stop caffeine
             consumption from 48 hours prior to dosing in Period 1 until Discharge

          -  Have consumed grapefruit or grapefruit-containing products 30 days prior to enrollment
             or unwilling to abstain during the study

          -  Have a documented or suspected history of glaucoma

          -  Participants unwilling to adhere to the smoking restrictions of the Clinical Research
             Unit (CRU) while a resident of the CRU

          -  Use of known inhibitors and/or inducers of CYP2C19 and CYP2D6 (with the exception of
             quinidine per protocol) 30 days prior to enrollment or are unwilling to avoid them
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylethyl Alcohol</mesh_term>
    <mesh_term>Quinidine gluconate</mesh_term>
    <mesh_term>Quinidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 17, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

